Browsing Tag
Blood Cancer Drug
3 posts
AbbVie’s ibrutinib, venetoclax combo succeeds in phase 3 GLOW study
AbbVie said that the phase 3 GLOW study in chronic lymphocytic leukemia (CLL) investigating the combination of IMBRUVICA…
Cyclacel Pharmaceuticals’ sapacitabine fails to meet primary endpoint in Phase 3 blood cancer trial
Cyclacel Pharmaceuticals, a New Jersey-based biopharmaceutical company, announced that its experimental blood cancer drug, sapacitabine (CYC682), did not…
Pfizer’s inotuzumab ozogamicin gains FDA priority review in acute lymphoblastic leukemia
Pfizer Inc. has received a priority review designation from the U.S. Food and Drug Administration (FDA) for its…